PERFORMANCE IN INITIATING CLINICAL RESEARCH (Q4, 2014/15)

Research Ethics Committee Reference Number	Name of Trial	Date of Receipt of Valid Research Application	Date of First Patient Recruited	Benchmark Met?	Reason for not meeting benchmark
09/H1005/28	Molecular genetics of adverse drug reactions: from candidate genes to genome wide association studies.	31/10/2014	02/12/2014	Yes	Benchmark met
12/LO/1078	A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, velcade and dexamethasone (CVD) for first relapse or primary refractory multiple myeloma patients.	16/05/2014	03/07/2014	Yes	Benchmark met
12/LO/1177	Streamlining Staging of Lung Cancer with Whole Body MRI	27/10/2014	08/12/2014	Yes	Benchmark met
12/LO/1966	A Phase 3, Randomized, Placebocontrolled, Parallelgroup, Multicenter, Doubleblind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Refractory to Somatostatin Analog (SSA) Therapy	01/08/2014	14/08/2014	Yes	Benchmark met
12/WM/0199	A pragmatic randomised controlled trial assessing the impact of a low calorie Cambridge based diet programme (CDBP) on weight loss in obese patients with Type 2 diabetes mellitus treated with insulin	15/10/2014	04/11/2014	Yes	Benchmark met
12/WM/0373	A randomised trial in new hearing aid users to measure the benefit of using 4 pre-set configurations of hearing aids with self learning characteristics	04/11/2014	14/11/2014	Yes	Benchmark met
12/YH/0504	Assessment of the efficacy and safety of a new wound dressing in the local treatment of diabetic foot ulcers: A Prospective, randomised, controlled, doubleblind, European multicentre clinical trial.	12/02/2015	31/03/2015	Yes	Benchmark met
13/EE/0364	A Randomized, Doubleblind, Multicenter Phase 2 Trial of Denosumab in Combination with Chemotherapy as Firstline Treatment of Metastatic Nonsmall Cell Lung Cancer.	24/06/2014	09/07/2014	Yes	Benchmark met
13/EM/0348	Safety and Efficacy assessment of Monoprost? in comparison with Lumigan? 0.01 % and Lumigan? 0.03% UD, in patients with primary open angle glaucoma or ocular hypertension, stabilized by Lumigan? 0.01 % with ocular surface intolerance.	10/03/2014	07/05/2014	Yes	Benchmark met
13/EM/0395	Treatment of Advanced Glaucoma Study (TAGS): A multicentre randomised controlled trial comparing primary medical treatment with primary augmented trabeculectomy for people with newly diagnosed advanced glaucoma	11/09/2014	03/11/2014	Yes	Benchmark met
13/EM/0460	A RANDOMIZED, MULTICENTER, OPEN-LABEL TRIAL COMPARING CHEMOTHERAPY PLUS TRASTUZUMAB PLUS PERTUZUMAB VERSUS CHEMOTHERAPY PLUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2 POSITIVE PRIMARY BREAST CANCER	12/08/2014	20/10/2014	Yes	Benchmark met
13/LO/0595	COgnitive behavioural therapy vs standardised medical care for adults with Dissociative nonEpileptic Seizures: A multicentre randomised controlled trial.	31/10/2014	03/12/2014	Yes	Benchmark met
13/LO/1463	An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease	23/10/2014	22/12/2014	Yes	Benchmark met
13/LO/1775	The PRAETORIAN Trial: A prospective, randomised comparison of subcutaneous and transvenous implantable cardioverter defibrillator therapy	26/11/2014	08/12/2014	Yes	Benchmark met
13/LO/1814	A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of Pergoveris? (follitropin alfa and lutropin alfa) and GONAL-f? (follitropin alfa)	30/06/2014	28/08/2014	Yes	Benchmark met
13/NS/0002	A multicentre randomised controlled trial of extracorporeal shockwave lithotripsy, as first treatment option, compared with direct progression to uretrosepctic treatment, for ureteric stones	19/09/2014	27/10/2014	Yes	Benchmark met
13/NW/0002	Prospective, randomised, controlled investigation comparing the safety and performance of 032-11 Surgical Haemostat 2g Applicator with FLOSEAL Hemostatic Matrix as an adjunctive haemostat in cardiac surgery and thoracic aortic surgery -VICTORY Study	10/12/2014	20/01/2015	Yes	Benchmark met

13/NW/0778	A double-blind, randomised, placebo-controlled, Phase II study to evaluate ProCervix efficacy to clear HPV 16 and HPV 18 infection in women with normal cytology or ASCUS/LSIL	11/08/2014	03/10/2014	Yes	Benchmark met
13/SW/0132	Male synthetic sling versus Artificial urinary Sphincter Trial for men with urodynamic stress incontinence after prostate surgery: Evaluation by Randomised controlled trial	01/10/2014	05/12/2014	Yes	Benchmark met
13/WM/0419	MAMMO-50: Mammographic surveillance in breast cancer patients aged 50 years and over	16/07/2014	19/09/2014	Yes	Benchmark met
13/WS/0056	Cancer and Venous Access (CAVA) A randomised controlled trial with associated qualitative research of venous access devices for the delivery of long-term chemotherapy	03/02/2015	24/03/2015	Yes	Benchmark met
13/YH/0162	HABSelect	17/09/2014	12/11/2014	Yes	Benchmark met
13/YH/0317	Current Steering to Optimize Deep Brain Stimulation	02/10/2014	16/10/2014	Yes	Benchmark met
13LO/0326	A RANDOMIZED, PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMA	09/01/2015	12/02/2015	Yes	Benchmark met
14/EE/0086	Neuromuscular Electrical Stimulation (NMES) in Patients with Intermittent Claudication	29/10/2014	09/12/2014	Yes	Benchmark met
14/EE/0188	The Effects of Electronic Cigarettes on the Microcirculation of the Hand	28/07/2014	27/08/2014	Yes	Benchmark met
14/EE/0193	Adjuvant benefit of Neuromuscular Electrical Stimulation (NMES) in Supervised Exercise in Patients with Intermittent Claudication	20/10/2014	08/12/2014	Yes	Benchmark met
14/LO/0083	An Open Label Study Examining the Efficacy and Cardiovascular Risk of Immediate Versus Deferred Switch From a Boosted PI to Dolutegravir (DTG) in HIV Infected Patients With Stable Virological Suppression	22/09/2014	07/10/2014	Yes	Benchmark met
14/LO/0121	A Phase II, Double Blind, Randomised, Placebo-Controlled Study of the AKT Inhibitor AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer	27/08/2014	07/10/2014	Yes	Benchmark met
14/LO/0302	A UK single centre study on the preoperative characterisation of ovarian tumours and conservative management of benign looking adnexal masses	21/03/2014	21/05/2014	Yes	Benchmark met
14/LO/0339	The ACORN study: Coping and Relaxation in Pregnancy	04/11/2014	03/12/2014	Yes	Benchmark met
14/LO/0369	Determining the pathophysiological role of slow conduction channels identified by Ripple Mapping of the ventricular scar	30/07/2014	05/08/2014	Yes	Benchmark met
14/LO/0665	A Phase III OpenLabel Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK5172/ MK8742 in TreatmentNa?ve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who are on Opiate Substitution Therapy.	28/08/2014	10/09/2014	Yes	Benchmark met
14/LO/0704	The Effect of Short term Dietary Supplementation of Fermentable Carbohydrates on Propionate Production and Appetite Measures: A Pilot Study	17/06/2014	10/07/2014	Yes	Benchmark met
14/LO/0717	A Multicenter Phase 3 Randomized Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukaemia.	19/09/2014	10/11/2014	Yes	Benchmark met
14/LO/0824	A Double-Blind, Randomised, Placebo-Controlled Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Single and Multiple Doses of PP 1420 in Healthy Subjects.	15/08/2014	07/10/2014	Yes	Benchmark met
14/LO/0854	Electrical stimulation in peripheral arterial disease	15/08/2014	27/08/2014	Yes	Benchmark met
14/LO/0871	A randomised controlled trial of a duodenal sleeve bypass device (EndoBarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes	12/11/2014	28/11/2014	Yes	Benchmark met
14/LO/0882	A PHASE III, OPEN-LABEL, MULTICENTER,RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY	05/08/2014	06/08/2014	Yes	Benchmark met
14/LO/1123	REBIRTH: Liver Regeneration: a singlecentre, prospective, randomised controlled trial comparing radiofrequency assisted liver partition with portal vein ligation (RALPP) with portal vein embolization (PVE)	11/08/2014	28/08/2014	Yes	Benchmark met

14/LO/1197	Phase IB open label study to assess the safety, pharmacokinetics and clinical activity of Acelarin (NUC-1031) given on days 1 & 8 with carboplatin on day 1, every three weeks for 6 cycles in participants diagnosed with recurrent ovarian cancer.	30/10/2014	27/11/2014	Yes	Benchmark met
14/LO/1381	A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily versus Raltegravir 400 mg Twice Daily, Each in Combination with TRUVADA	10/11/2014	08/01/2015	Yes	Benchmark met
14/LO/1493	A phase IV open-label, multi-centre, randomised, dual-arm, pilot study to assess the feasibility of switching individuals receiving Efavirenz with continuing Central Nervous System (CNS) toxicity, to Dolutegravir	22/01/2015	12/03/2015	Yes	Benchmark met
14/LO/1727	Diffusion tensor imaging (DTI tractography) in the prostate: Roadmapping the neurovascular bundle prior to radical prostatectomy.	24/11/2014	26/01/2015	Yes	Benchmark met
14/LO/1779	Incentive in Diabetic Eye Assessment by Screening (IDEAS) Trial	12/03/2015	19/03/2015	Yes	Benchmark met
14/LO/2060	A PROSPECTIVE MULTICENTRE STUDY OF EFFECTIVENESS OF RIPPLE MAPPING FOR ATRIAL TACHYCARDIA ABLATION	15/01/2015	02/02/2015	Yes	Benchmark met
14/NW/0130	A randomised, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL)	31/07/2014	04/09/2014	Yes	Benchmark met
14/NW/0290	Registry of Deep Brain Stimulation with the VERCISE? System: Vercise DBS Registry	21/11/2014	22/01/2015	Yes	Benchmark met
14/SC/0027	A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of Concomitant Administration of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01B + ChAd63 and MVA encoding ME-TRAP and also RTS,S/AS01B alone.	24/09/2014	06/10/2014	Yes	Benchmark met
14/SC/0084	Electrical Stimulation in Diabetic Foot Ulceration	10/07/2014	11/09/2014	Yes	Benchmark met
14/SC/0132	A phase I, open label study to assess the pharmacokinetic profile, safety and tolerability of OBE001 after a single oral administration in pregnant women with medically indicated pregnancy termination.	13/05/2014	30/06/2014	Yes	Benchmark met
14/SC/0157	Prehospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug administration In Cardiac arrest	27/11/2014	29/12/2014	Yes	Benchmark met
14/SC/0262	A Phase IV, prospective, open-label, uncontrolled, European Study in patients with neovascular Age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching From intravitreal Aflibercept to Ranlbizumab 0.5mg: SAFARI study	07/01/2015	10/03/2015	Yes	Benchmark met
14/SC/1014	A Randomized, DoubleBlind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas (The JANUS 1 study)	17/12/2014	15/01/2015	Yes	Benchmark met
14/SW/0091	Randomized, DoubleBlind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous NonSmall Cell Lung Cancer (NSCLC)	30/10/2014	06/01/2015	Yes	Benchmark met
14/WM/0057	Bypass vs. Angioplasty in Severe Ischaemia of the Leg: Multicentre randomised controlled trial to compare the clinical and costeffectiveness of a ?vein bypass first? with a ?best endovascular first? revascularisation strategy	08/12/2014	01/02/2015	Yes	Benchmark met
14/WM/0159	Safety of Nasal Influenza Immunisation in Egg Allergic Children The SNIFFLE 2 study	02/10/2014	13/10/2014	Yes	Benchmark met
14/WM/0185	Intranasal diagnostics in food allergy (INDY): a feasibility study	17/09/2014	27/10/2014	Yes	Benchmark met
14/WM/1056	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV	05/09/2014	01/10/2014	Yes	Benchmark met
14/WS/1096	Uncovering obesity and diabetes related complex metabolic dysregulation associated to endometrial cancer	19/11/2014	15/01/2015	Yes	Benchmark met
14/YH/0047	Intraoperative raman spectoscopy for immediate human brain tumour diagnosis and detection of tumour margin	11/08/2014	02/10/2014	Yes	Benchmark met
14/YH/0049	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of the Combined Lysis of Thrombus with Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization (CLOTBUST-ER) in Acute Ischemic Stroke.	08/08/2014	41919	Yes	Benchmark met
14/YH/0123	An Expanded Access Protocol for Idelalisib (GS-1101) in Combination with Rituximab for Relapsed, Previously Treated Subjects with Chronic Lymphocytic Leukemia.	08/07/2014	41877	Yes	Benchmark met

14/YH/1057	A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects with Chronic Genotype 3 HCV Infection	29/08/2014	41901	Yes	Benchmark met
14/YH/1153	An Open-Label, Extension Study of the Effects of Leuco-methylthioninium bi (hydromethanesulfonate) in Subjects with Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia	18/11/2014	42012	Yes	Benchmark met
10/H0302/51	Improving the management and control of tuberculosis among hard to reach groups	09/02/2015		Not yet applicable	70-day benchmark not yet expired
12/EE/0029	A 12 week, single centre, open label study to evaluate the effect of fesoterodine flexible dosing regimen on the sexual function of women with overactive bladder.	22/01/2015		Not yet applicable	70-day benchmark not yet expired
13/LO/1224	Assessing sensitivity to and tolerability of intravenous psilocybin in patients with treatment-resistant depression: A Pilot Study	12/03/2015		Not yet applicable	70-day benchmark not yet expired
13/NI/0160	Management of myocardial injury After NoncArdiac surgGEry (MANAGE)	25/03/2015		Not yet applicable	70-day benchmark not yet expired
13/NW/0714	ECASS-4: ExTEND - European Cooperative Acute Stroke Study-4 Extending the time for Thrombolysis in Emergency Neurological Deficits	03/02/2015		Not yet applicable	70-day benchmark not yet expired
14/EM/1059	A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura	05/02/2015		Not yet applicable	70-day benchmark not yet expired
14/EM/1060	A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura	09/03/2015		Not yet applicable	70-day benchmark not yet expired
14/EM/1302	Neuromuscular Electrical Stimulation for the treatment of Diabetic Peripheral Neuropathy.	13/02/2015		Not yet applicable	70-day benchmark not yet expired
14/LO/0117	Ablation versus anti-arrhythmic therapy for reducing all hospital episodes from recurrent atrial fibrillation.	27/03/2015		Not yet applicable	70-day benchmark not yet expired
14/LO/0673	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia.	13/02/2015		Not yet applicable	70-day benchmark not yet expired
14/LO/1728	A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination with Topotecan (Hycamtin®) in Patients with Solid Tumors	03/03/2015		Not yet applicable	70-day benchmark not yet expired
14/LO/1833	Pilot study to evaluate diffusion weighted MRI (DWMRI) Whole Body MRI in relapsed Multiple Myeloma at 3T: test re test, early response assessment and exploratory imaging of renal function	16/02/2015		Not yet applicable	70-day benchmark not yet expired
14/LO/2044	The role of intrinsic cardiac autonomic nervous system in human arrhythmogensis	16/03/2015		Not yet applicable	70-day benchmark not yet expired
14/LO/2078	A Phase 1, first in man, study to assess the safety, pharmacokinetic profile and antiretroviral efficacy of C34-PEG4-Chol, a novel peptide fusion inhibitor for the treatment of HIV-infection	26/02/2015		Not yet applicable	70-day benchmark not yet expired
14/NE/1062	PHOTOdynamic versus white light-guided treatment of non-muscle invasive bladder cancer: randomised trial of clinical and cost-effectiveness	18/03/2015		Not yet applicable	70-day benchmark not yet expired
14/NW/0036	ESPAC 5 - Four arm, prospective, multicentre, randomised feasibility trial of immediate surgery compared with neoadjuvant chemotherapies and neoadjuvant chemoradiotherapy	12/03/2015		Not yet applicable	70-day benchmark not yet expired
14/NW/1027	Evaluation of Sorafenib in combination with local microtherapy guided by GdEOBDTPA enhanced MRI in patients with inoperable hepatocellular carcinoma	16/02/2015		Not yet applicable	70-day benchmark not yet expired
14/SC/1056	A multicentre randomised controlled trial to compare the efficacy of ex-vivo oxygenated hypothermic machine perfusion with non-oxygenated hypothermic machine perfusion of kidneys older than 50 years of age and donated after circulatory death	04/03/2015		Not yet applicable	70-day benchmark not yet expired
14/SC/1206	The Efficacy and Cost effectiveness of Real Time Ultrasound Elastography in The Investigation Of Thyroid Nodules and the diagnosis of thyroid cancer.	09/03/2015		Not yet applicable	70-day benchmark not yet expired
14/WM/0083	A Phase III Trial of Surgery versus Active Monitoring for Low Risk Ductal Carcinoma in Situ (DCIS)	06/03/2015		Not yet applicable	70-day benchmark not yet expired
14/WM/0162	Barrier Enhancement for Eczema Prevention - BEEP	16/03/2015		Not yet applicable	70-day benchmark not yet expired
14/WM/1262	An Open Label Study of Sofosbuvir/GS5816 FixedDose Combination in Subjects with Chronic HCV Infection	23/03/2015		Not yet applicable	70-day benchmark not yet expired
14/WM1055	A prospective, multicenter, randomized, double blind, placebocontrolled, 2parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI to placebo in combination with FOLFIRI	09/03/2015		Not yet applicable	70-day benchmark not yet expired
14/WS/1105	REVEAL 101MS408 Multicenter study of Natalizumab v Fingolimod in MS	26/03/2015		Not yet applicable	70-day benchmark not yet expired

10/H0801/67	Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Risk Prostate Cancer: Feasiblity Study	11/06/2014		No	Study team actively screening for patients. No patients recruited yet.
12/EE/0231	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N?Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone	07/04/2014		No	Closed by sponsor; Rare disease study
12/LO/0858	An OpenLabel Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon a2a and Ribavirin (pegIFN/RBV) in Chronic Hepatitis C Virus (HCV) Infected	01/05/2014	29/07/2014	No	Treatment roll-over study. Not possible to recruit earlier as clinical outcomes from original feeder studies were unknown.
12/LO/0923	A Phase 3, randomized, doubleblind, controlled trial of cabozantinib (XL184) vs. mitoxantrone plus prednisone in men with previously treated symptomatic castrationresistant prostate cancer	23/05/2014		No	Closed by sponsor
12/LO/0980	PROTOCOL EC-FV-06: A RANDOMIZED DOUBLE-BLIND PHASE 3 TRIAL COMPARING VINTAFOLIDE (EC145) AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD/DOXIL?/CAELYX?) IN COMBINATION VERSUS PLD IN PARTICIPANTS WITH PLATINUM-RESISTANT OVARIAN CANCER	20/03/2014		No	Closed by sponsor
12/LO/1889	Openlabel,single arm extension study to the doubleblind,randomized, multicenter, placebo controlled,parallel group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in multiple sclerosis	23/04/2014	11/07/2014	No	Study experienced long contract / budget negotiations.
12/NE/0343	Clarifying the management of men with recurrent urethral stricture: A pragmatic multicentre randomised superiority trial of open urethroplasty versus endoscopic urethrotomy	01/10/2014		No	Rare disease study.
12/SS/0109	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches	28/04/2014	30/09/2014	No	Despite ongoing patient screening activity at this site, no eligible patients have been seen during the reported period.
12/SS/0138	REstart or STop Antithrombotics Randomised Trial - RESTART	29/05/2014		No	Yet to recruit despite daily screening. Restrictive study exclusion criteria.
12/SW/0264	Pulmonary Arterial Hypertension: Working on Anxiety and Stress	06/08/2014	15/01/2015	No	Rare disease.
12/SW/0378	Effect of BivaliRudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)	14/04/2014	19/09/2014	No	Bereavement within study team
13/EE/0214	A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Risistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial	24/03/2014	10/06/2014	No	US FDA regulations
13/EE/0429	A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malignancies.	07/01/2014	16/06/2014	No	Contracting delays
13/EE/0444	Maximizing CRT Delivery by using Multipolar Coronary Sinus Lead Acuity x4	05/02/2014	24/07/2014	No	Lengthy budget/contract negotiation.
13/LO/0150	A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib	21/08/2014		No	Rare disease study. 3 patients identified but all failed eligibility criteria.
13/LO/0451	The United Kingdom Transcatheter Aortic Valve Implantation (UK TAVI) Trial. A multi-centre randomised controlled trial to assess the clinical effectiveness and cost-utility of TAVI, compared with conventional surgical aortic valve replacement	11/07/2014		No	Study team actively screening for suitable patients but none consented; continuing to screen against current protocol.
13/LO/1050	A Multicenter, Randomized, OpenLabel, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in FirstLine Treatment of Subjects With Unresectable Hepatocellular Carcinoma	02/12/2013	10/07/2014	No	Sponsor delays; Contracting delays
13/LO/1115	UK Multicentre Open-label Randomised Controlled Trial Of IV Iron Therapy In Incident Haemodialysis Patients	10/06/2014	20/08/2014	No	First patient consented before 70-days, but was ineligble. First eligible patient was recruited just one day after deadline.
13/LO/1233	MAGnetic NAnoparticle thermoaBLATion Retention and Maintenance in prostatE: A Phase 0 Study in Men (MAGNABLATE I Trial)	04/08/2014	10/12/2014	No	Sponsor suspended study due to patient safety issue. First patient has subsequently been recruited immediately after suspension lifted.
13/LO/1323	The efficacy and safety of Ferriprox? for the treatment of transfusional iron overload in patients with sickle cell disease or other anaemias	05/06/2014	30/10/2014	No	SIV has been postponed due to a delay with delivery of IMP.
13/LO/1557	A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients	13/05/2014	09/03/2015	No	Several patients screened however eventually identified as non-eligible. Problem in recruiting patients all over UK due to study design. Inclusion criteria will probably be amended.
13/LO/1682	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian,	08/09/2014		No	Eligible patients were identified and approached in under 70 days, but declined to take part.

13/LO/1758	A Phase III, Randomized, PlaceboControlled, ParallelGroup, DoubleBlind Clinical Trial to Study the Efficacy and Safety of MK8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer?s Disease (Prodromal AD).	13/03/2014	13/06/2014	No	ARSAC license delays / specific patient group. Sponsor praised site for being the first to recruit nationally and also for having a low screen fail rate.
13/LO/1916	Reproduceability of the 11C-PBR28 PET signal	11/12/2013	03/07/2014	No	Permissions delayed or denied; Staff availability issues
13/NE/0126	An exploratory, randomised, doubleblind, controlled study to assess the effect of an Amino Acid Based Formula with a synbiotic blend on gut microbiota and stool in infants with suspected gastrointestinal Non IgE mediated cow's milk allergy	18/09/2014		No	Inclusion criteria difficult.
13/NI/0143	Scheduling nab-paclItaxEl with GEmcitabine (SIEGE): Randomised phase II trial to investigate two different schedules of nab-paclitaxel (Abraxane) combined with gemcitabine as first line treatment for metastatic pancreatic adenocarcinoma	29/07/2014		No	Rare disease study. Study team actively looking for patients.
13/NI/0188	A singlearm trial to evaluate the effectiveness of PCI of de novo 3vessel disease applying the SYNTAX score II with pressure wire functional assessment and IVUS guidance, using an everolimuseluting stent with biodegradable abluminal coating	03/04/2014	16/07/2014	No	NHS permission delays; safety concerns in relation to imaging component of study needed to be clarified with Sponsor.
13/NW/0634	A Phase 1b, multicenter, openlabel, dose escalation study of GSK2256098 (FAK inhibitor) in combination with Trametinib (MEK inhibitor) in subjects with advanced solid tumors	19/11/2013	15/05/2014	No	Staff availability issues
13/NW/0697	PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246	12/12/2013	19/05/2014	No	Query regarding imaging requirements; recommended that an amendment be submitted; contracting delays
13/NW/0702	A Phase III, randomised, multicentre,open label study of active symptom control (ASC) alone or ASC with oxaliplatin/5FU chemotherapy for patients with locally dvanced/metastatic biliary tract cancers	28/03/2014	16/06/2014	No	Rare disease. incidence is approximately 1 in 100,000.
13/SC/0559	A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome	17/09/2014		No	Delay with SIV; also a rare disease.
13/SC/0589	Optimisation of Onpulse technology for patients with post surgical or vascular oedema	08/01/2014	20/07/2014	No	Permissions delayed or denied; Staff availability issues; Contracting delays
13/WA/0117	A randomised phase II trial of Olaparib maintenance versus placebo monotherapy in patients with non-small cell lung cancer	06/10/2014	16/12/2014	No	Delays in site activation. ICHT still managed to quickly recruit first patient 4 days after Sponsor green light (missed benchmark by 1 day).
13/WS/0172	A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	06/08/2014		No	Recruitment suspended by Sponsor (Oct 2014); due to re-open March 2015. ICHT site opened end of August 2014 but no eligible patients seen in the 2 month period before suspension.
13/WS/0282	Prospective, single-arm, global multi-center study to evaluate treatment of obstructive superficial femoral artery and/or popliteal lesions wiht a novel paclitaxel coated percutaneous angioplasty ballon.	12/02/2014	02/10/2014	No	Regulatory approvals delay (MHRA). NHS Permission delayed due to change of CRO study management team which led to delays in contract approval. First patient not yet recruited - no suitable patients have been found despite screening.
13/YH/0152	A Randomised Trial of the FLAMSABU Conditioning Regimen in Patients with Acute Myeloid Leukaemia and Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation	28/07/2014	13/11/2014	No	Delays in the procurement of Amsacrine (study drug). Drug only made available in the UK in October 2014. First patient then recruited in mid-November.
13/YH/0281	Evaluation of [18F]FET?AGTOCA for the imaging of NETs	10/03/2014	22/05/2014	No	First patient consented before 70-days, but was ineligble. First eligible patient was recruited just three days after deadline.
13/YH/0424	Randomised trial of rapid outpatient rehydration versus hospital admission for management of hyperemesis gravidarum	29/05/2014	20/01/2015	No	Study suspended due to issues with clinical nursing resource support.
14/EM/0130	A Phase 3, Open-Label, Randomized Study of Quizartinib (AC220) Monotherapy vs. Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory to, or Relapsed after, First-Line Treatment	28/11/2014		No	Rare disease.
14/EM/0186	A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis	15/09/2014		No	Very rare disease study (less than 1 in 500,000).
14/LO/0067	The control of brain networks after traumatic brain injury: a neuroimaging and neuropsychological study of dopamine and cognition	28/04/2014	08/07/2014	No	Permissions delayed or denied; Radiopharmaceutical supply delays
14/LO/0102	A First Time in Human, Double Blind, Randomised, Placebo Controlled Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Intravenous Doses of SNF472 in Healthy Male Volunteers	15/10/2014	20/01/2015	No	Study opened to recruitment but no eligible patients yet consented.
14/LO/0130	Temperature Controlled Laminar Airflow (TLA) treatment in children with severe atopic eczema-Prospective Pilot Study	23/04/2014	15/01/2015	No	PI on leave - not possible to replace expertise for this study.

14/LO/0362	Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel-group, 24-week study to assess the efficacy, safety and tolerability of macitentan in subjects with inoperable chronic thromboembolic pulmonary hypertension	07/07/2014		No	Rare disease study.
14/LO/0521	A prospective, randomized, open label, two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia positive CML after two different durations of consolidation treatment with nilotinib 300mg BID.	15/07/2014	19/01/2015	No	Site initiated by Sponsor on day 65. Also a rare disease study (affects 1 in 100,000).
14/LO/0600	Preventing Recurrent Gestational Diabetes Mellitus with Early Metformin Intervention	19/09/2014	27/01/2015	No	Participant identification more challenging than anticipated when study discussed at feasibility assessment due to changes in clinical pathways.
14/LO/0864	A double blind, randomised controlled trial to assess the efficacy of paravertebral blocks for analgesia after cardiac surgery	13/08/2014	27/10/2014	No	Patients have been seen but have not consented to join the study.
14/LO/0865	A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy	07/11/2014		No	Initial NHS permission excluded use of tissue bank to store patient samples. Study team decided to wait until full approval was in place before starting to recruit. Several patients have been approached since 9th Jan 2015 (63 days after valid submission) but declined to take part.
14/LO/1053	A Phase 3 Randomised double blind Active study Evaluating Memelotinib vs Ruxolitinib in subjects with primary Myelofibrosis (PMF) or Post-poly cythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)	28/08/2014		No	Delays in supplying study drug. This study has not opened yet anywhere in the UK or Europe due to drug supply problems. ICHT is one of only two UK sites that have issued approval and are ready to start as soon as the drug is available. Expected activation for UK sites is end of Q1 2015.
14/LO/1428	A phase 3 multi-centre double-masked randomised controlled trial of adjunctive intraocular and periocular steroid (triamcinolone acetonide) versus standard treatment in eyes undergoing vitreoretinal surgery for open globe trauma	06/01/2015		No	Very specific eligibility criteria, making this essentially a rare disease (relies on a very specific eye trauma patient coming into A&E; unpredictable and rare).
14/NE/1072	A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED BRONCHOSCOPY STUDY TO EVALUATE THE EFFECTS OF LEBRIKIZUMAB ON AIRWAY EOSINOPHILIC INFLAMMATION IN PATIENTS WITH UNCONTROLLED ASTHMA ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER MEDICATION	16/01/2015		No	Delays in sponsor sending equipment needed for the study. Suitable volunteers have been approached but were either inegible or declined.
14/NW/0008	Golimumab: A Phase 4, UK Open Label, Single arm Study on its Utilization and Impact in Ulcerative Colitis	17/09/2014	12/12/2014	No	Patients being seen and consented but none yet found eligible.
14/NW/0156	OlympiAD - Olaparib monotherapy V Physicians choice chemotherapy	25/06/2014		No	Rare patient group (less than 1 in 2000). Site continues to screen every day.
14/SC/0037	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICIACY AND SAFETY STUDY OF GANTENERUMAB IN SUBJECTS WITH MILD ALZHEIMER?S DISEASE	12/05/2014	03/10/2014	No	Delays in recruiting to this study caused by pre-identified patients needing to be stabilised on cholinesterase inhibitors before meeting inclusion criteria, i.e. patients are actively being screened for the study but are not eligible.
14/SC/0038	PET IMAGING SUBSTUDY ASSOCIATED WITH: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICIACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH MILD ALZHEIMER?S DISEASE	14/01/2014	22/07/2014	No	Permissions delayed or denied; Sponsor delays
14/SC/0178	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia	06/06/2014	31/10/2014	No	This is a rare disease study (5.1 per 100,000 in Europe). All possible patients continue to be screened.
14/WM/0170	A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis,	14/10/2014	19/02/2015	No	Myelofibrosis is a rare disease.
14/YH/0034	IciCLLe: Assessment of the Mechanism of Action of Ibrutinib (PCI32765) in Bcell Receptor Pathway Inhibition in CLL.	29/05/2014	11/08/2014	No	Very rare disease study (0.6 in 10,000 in males & 0.4 in 10,000 in females).
14/YH/0085	Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab.	26/09/2014	42053	No	Very rare disease study (0.6 in 10,000 in males & 0.4 in 10,000 in females).